Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
Manel AllegMorgane SolisSeyyid BalogluFrançois CottonPhilippe KerschenBertrand BourreGuido AhleJean-Pierre PruvoXavier LeclercPatrick VermerschCaroline PapeixÉlisabeth MaillartCaroline HouillierCécile Moluçon ChabrotBéatrice ClaiseSandra MalakGuillaume Martin-BlondelFabrice BonnevilleAlexis CaulierJean-Pierre MarolleauJérôme Tamburini BonnefoyPhilippe AgapeCéline KennelXavier RousselAdrien ChauchetJérôme De SezeSamira Fafi-KremerStéphane KremerPublished in: European radiology (2020)
• Nowadays, PML is emerging as a complication of new effective therapies based on monoclonal antibodies. • Natalizumab-associated PML shows more inflammatory signs, a perivascular distribution "the milky way," and more cortex involvement than rituximab- and HIV-associated PML. • MRI differences are probably related to higher levels of immunosuppression in HIV patients and those under rituximab therapy.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- multiple sclerosis
- hiv infected
- diffuse large b cell lymphoma
- hiv positive
- human immunodeficiency virus
- end stage renal disease
- hiv aids
- hiv testing
- magnetic resonance imaging
- contrast enhanced
- hepatitis c virus
- chronic lymphocytic leukemia
- hodgkin lymphoma
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- men who have sex with men
- oxidative stress
- computed tomography
- stem cells
- diffusion weighted imaging
- functional connectivity
- patient reported outcomes
- bone marrow
- cell therapy
- mesenchymal stem cells